Skip to main content
Premium Trial:

Request an Annual Quote

Sysmex, Optim to Establish Digital Medicine Joint Venture

NEW YORK – Japanese diagnostics device firm Sysmex and artificial intelligence company Optim said on Friday  that they have agreed to establish a joint venture aimed at the development and operation of services and platforms for digital medicine.

The two companies formed a business alliance this February and have been collaborating on initiatives to combine Sysmex’s global sales and service network with Optim’s artificial intelligence and data management technologies, including a product it calls Optim Cloud IoT OS. 

Under the newly agreed upon joint venture, the partners said that they plan to develop and test new diagnostic methods that combine image information from gene tests with AI analysis, as well as to use AI for image processing of various data obtained from existing Sysmex analyzers. 

The venture, which they plan to establish in January, will also seek collaborations with pharmaceutical companies, manufacturers of medical devices, and other companies, the firms said. Some discussions are already ongoing with potential pharma and device partners.

Financial terms of the agreement were not disclosed.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more